TrialHuman vaccines2011

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.

Tino F Schwarz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.